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Abstract
Background: We examined the effect of chronic administration of angiotensin IV (AngIV) on the vascular
alterations induced by type 1 diabetes in mice.
Methods: Diabetes was induced in adult Swiss mice with a single injection of streptozotocin (STZ). Mice were
treated subcutaneously with AngIV (1.4 mg/kg/day) either immediately following diabetes induction (preventive
treatment), or treated with AngIV (0.01 to 1.4 mg/kg), alone or with the AT4 receptor antagonist Divalinal or the
AT2 receptor antagonist PD123319, for two weeks after 4 weeks of diabetes duration (rescue treatment).
Acetylcholine-induced, endothelium-dependent relaxation (EDR) was measured in isolated aortic rings preparations.
Histomorphometric measurements of the media thickness were obtained, and nitric oxide (NO) and superoxide anion
production were measured by electron paramagnetic resonance in aorta and mesenteric arteries. The effect of diabetes
on mesenteric vascular alterations was also examined in genetically modified mice lacking the AT2 receptor.
Results: Induction of diabetes with STZ was associated with a progressive decrease of EDR and an increase of the aortic
and mesenteric media thickness already significant after 4 weeks and peaking at week 6. Immediate treatment with
AngIV fully prevented the diabetes-induced endothelial dysfunction. Rescue treatment with AngIV implemented after
4 weeks of diabetes dose-dependently restored a normal endothelial function at week 6. AngIV blunted the thickening
of the aortic and mesenteric media, and reversed the diabetes-induced changes in NO and O2
•– production by the
vessels. The protective effect of AngIV on endothelial function was completely blunted by cotreatment with Divalinal,
but not with PD123319. In contrast, both the pharmacological blockade and genetic deletion of the AT2 receptor
reversed the diabetes-induced morphologic and endothelial alteration caused by diabetes.
Conclusions: The results suggest an opposite contribution of AT2 and AT4 receptors to the vascular alterations caused
by streptozotocin-induced diabetes in mice, since chronic stimulation of AT4 by AngIV and inhibition of AT2 similarly
reverse diabetes-induced endothelial dysfunction and hypertrophic remodeling, and increase NO bioavailability.
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Background
Diabetes mellitus is a major cause of morbidity and mor-
tality worldwide and is associated with an increased risk
of cardiovascular disease [1]. Indeed, cardiovascular dis-
orders in diabetic patients include premature athero-
sclerosis, manifest as myocardial infarction and stroke
as well as impaired cardiac function, predominantly dia-
stolic dysfunction [2]. The precise initiating event of
these disorders is unknown although dysfunction within
the endothelium is thought to be an important early
contributor. The endothelium is crucial for maintenance
of vascular homeostasis, ensuring that a balance remains
between vasoactive factors (such as angiotensin II
(AngII) and nitric oxide (NO)), controlling its perme-
ability, adhesiveness, and integrity, but this balance ap-
pears compromised by diabetes [3,4].
AngII, the main bioactive peptide of the renin angio-
tensin system (RAS), plays a pivotal physiological role in
the regulation of salt homeostasis, kidney function and
blood pressure through binding to AT1 receptor. It has
been discovered that besides its systemic regulatory
functions, AngII subserves paracrine and autocrine ac-
tions in various organ and tissues, including the heart
and the vessels, where it is locally released [5]. AngII
was shown to stimulate the expression of leukocytes ad-
hesion molecule, and the release of inflammatory cyto-
kines. Moreover, AngII increases the oxidative stress
thereby impairing the physiological endothelial balance
between NO and reactive oxygen species (ROS). AngII
thus emerged as a pivotal mediator of pathophysiological
mechanisms involving functional endothelial impairment
and vascular hypertrophy in a number of clinical disor-
ders such as essential hypertension [6], atherosclerosis
[7], and diabetes [8].
Reducing AngII formation or signaling with angio-
tensin converting enzyme inhibitors (ACEIs) or AT1
receptor antagonists (ARBs) thus appeared as an ideal
therapeutic approach, expected to provide beneficial
protective effect beyond the blood pressure reduction.
Although both class of drugs have been proven effective
to lower cardiovascular morbidity and mortality in large
clinical trials [9,10], further therapeutic improvements
still remain needed to reduce the excessive burden of
cardiovascular diseases, especially in diabetes patients.
During the last decade, it has become increasingly
clear that the renin-angiotensin-aldosterone system
(RAAS) does not resume to AngII and the AT1 receptor,
and that other receptors and angiotensin peptides
modulate and mitigate or counteract the action of AngII.
Studies conducted in two AT2-null mice strains [11,12]
suggested that the alternative receptor to AngII, AT2,
counter regulates the AT1-mediated antinatriuretic and
pressor actions of AngII, by a mechanisms involving in-
creased NO production. This conclusion was further
supported by pharmacological studies in rat [13-15].
Furthermore, other angiotensin peptides, such as angio-
tensin (1-7) and angiotensin (3-8) (AngIV), acting
through their respective specific receptors, mas and
AT4, also elicit effects that oppose the AngII AT1-
mediated action. AngIV increases blood flow in the renal
cortex and the brain, involving a vasodilator effect. The
AngIV-induced vasodilation is dependent on nitric oxide
release, since pretreatment with L-NAME abolished the
increase of cerebral and renal cortical blood flow [16,17].
An integrative understanding of the complex interac-
tions within the RAAS would certainly be helpful to
better identify therapeutic targets and refine RAS
pharmacological modulation in order to improve cardio-
vascular prevention. Of importance, the fact that AngIV
acutely administered opposes the systemic antinatriure-
tic and pressor effect of AngII does however not neces-
sarily imply that it could balance the chronic deleterious
vascular effects of AngII at the tissue level. An important
pioneer step forward was thus made recently with the
report by Vinh et al. that chronic AngIV treatment re-
verses endothelial dysfunction in ApoE-deficient mice
fed a high fat diet [18]. The same group further evi-
denced that in this experimental model of atheroscler-
osis, AngIV treatment was able to restore endothelial
function even when administered in mice with advanced
atheroma [19]. Then, the objective of the present study
was to examine if AngIV plays a similar protective role
against endothelial dysfunction and vascular hypertrophy
in the mice model of type 1 diabetes induced by
streptozotocin.
Methods
Animals
Swiss Male mice (20–30 g) were obtained from Depre
(Saint Doulchard, France). Additional experiments were
conducted in FVB/N mice (Institut für Experimentelle
und Klinische Pharmakologie und Toxikologie, Freiburg,
Germany) with deleted AT2R (Agtr2-/-) gene that were
compared to Agtr2+/+ mice [11]. Mice were maintained
in a room under controlled temperature (23°C), humid-
ity and air flow conditions, with a fixed 12-h light-dark
cycle, food and water available ad libitum. The current
investigation conformed to the guidelines for ethical care
of experimental animals of the European Community
and was approved by the French Agriculture Ministry
(authorization number B-00889).
Experimental design
Diabetes was induced by a single intraperitoneal injec-
tion of streptozotocin (STZ; 200 mg/kg) in citrate buffer
(pH 4.5) during the fasting state. Control animals re-
ceived equivalent doses of the citrate buffer solution.
Hyperglycemia occurred 2 days after STZ injection and
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was verified using an Accu-Check Active glucometer
(Roche, Lyon, France). Mice were considered to be dia-
betic and were included in the experimental diabetic groups
when blood glucose was ≥300 mg/dL (i.e. 16,6 mmol/L)
48 hours after the STZ injection. To examine the time
course of diabetes-induced vascular alterations, three
groups of diabetic mice were sacrificed after respectively 4,
6 and 8 weeks of diabetes duration.
Treatments
Preventive treatment with AngIV
Mice were anaesthetized with isoflurane 5% and an os-
motic mini-pumps (AlzetW model 2004, Palo Alto, CA)
containing sterile saline vehicle (NaCl 150 mmol/L) or
AngIV (1.4 mg/kg/day) were implanted subcutaneously
in the back of the neck for 4 weeks. Induction of dia-
betes with streptozotocin was performed immediately
after the surgical procedure.
Rescue treatment with AngIV
Other groups of diabetic mice were left untreated for
4 weeks after diabetes induction, and the various treat-
ments were implemented for two additional weeks. In
these mice with already established diabetes, the surgical
implantation of an osmotic pump was not possible and
the drugs were administered by a daily subcutaneous
injection. Separate groups of mice were treated with
AngIV (0.01; 0.03; 0.1; 0.3; 0.7 and 1.4 mg/kg/d),
whereas control diabetic group received daily injection
of the vehicle (NaCl 150 mmol/L). In parallel, two
groups of diabetic mice treated with AngIV (1.4 mg/kg/
d) were cotreated with the specific AT4 receptor antag-
onist Divalinal (2 mg/kg/d) or the AT2 specific antagon-
ist PD123319 (20 mg/kg/d) via subcutaneous injection.
Finally, a set of experiments was conducted in Agtr2+/+
or Agtr2-/- with or without STZ-induced diabetes.
Analytical methods
Weight and blood glucose of each mouse were recorded
before the sacrifice. Systolic blood pressure (SBP) was
measured at the end of treatment using non-invasive
tail-cuff apparatus (Bionics Instrument CO., LTD) in
anaesthetized mice. SBP was averaged from three con-
secutive measurements taken at intervals of 2-3 min.
Measurement of vascular reactivity of aortic rings and
mesenteric arteries
After sacrifice of mice, the thoracic aorta and the mesen-
teric artery were removed and placed in Krebs Bicarbonate
Buffer (KBF, PH 7.4) consisting of (mM): NaCl 118, KCl
3.7, KH2PO4 1, MgCl2 1.2, CaCl2 1.4, NaHCO3 25, and
glucose 11). The arteries were cleaned from fat and con-
nective tissues. First, aortic rings (3 mm in length) were
mounted isometrically, each ring was suspended between
two 100 μm stainless steel wires connected to an isometric
force transducer (Powerlab, AD Instruments). Aortic prepa-
rations were placed in chambers, kept at 37°C and bubbled
continuously with 95% O2 – 5% CO2 in Krebs Bicarbonate
Buffer (KBF) (pH 7.4). Tissues were stretched to their
optimum tension of 0.75 g and equilibrated and then
washed with fresh KBF at 15 min intervals for 60 min.
To determine endothelium–dependent relaxation, vessels
were maximally pre-contracted with phenylephrine (Phe;
10-6 M) before cumulative applications of acetylcholine
(ACh; 10-9 to 3.10-5 M). Finally, the vessels were subjected
to 10-5 M sodium nitroprusside (SNP), a donor of NO.
Second, mesenteric artery segments were dissected
and mounted on a wire-myograph (DMT, Aarhus, DK)
as previously described [20]. Briefly, two tungsten wires
(40 μm diameter) were carefully inserted into the arterial
lumen, and fixed to a force transducer and a micrometer,
respectively. Arteries were bathed in the PSS as de-
scribed above, and set to the baseline circumference.
After stabilizing for 45 min, artery viability was tested
using a potassium-rich solution (80 mM). Acetylcholine
(ACh) cumulative concentration–response curves (10-9
to 10-5 M) were then obtained after phenylephrine-
induced preconstriction (50% of maximal contraction).
Histomorphometric analysis
Sections of thoracic aorta and mesenteric artery were in-
cubated at 37°C in the physiological saline solution cal-
cium free (composition in mM: NaCl 130; KCl 3.7;
KH2PO4 1.2; NaHCO3 14.9; MgSO4 1.2; EGTA 2; glu-
cose 11) and supplemented with papaverin (10-6 M) and
SNP (10-5 M). After 20 minutes of incubation, these
arteries were fixed in 4% formaldehyde for 30 minutes.
Transverse sections were immersed in Tissue-Tek (Sakura,
Alphen aan den Rijn, The Netherlands) and snap frozen in
liquid nitrogen, than stored at -80°C until they were cut
into 7 μm thick. Sections were placed on Superfrost® slides
and were stained with orcein to view internal and external
elastic lamina. An image capture (200× magnification) was
performed on these sections using an optical microscope
(Olympus IMT-2) with a camera (Color Video Camera,
Sony). The thickness at 10 different points of the wall
media was measured and the media thickness was calcu-
lated, as previously described [21].
NO and superoxide anion (O2• –) determinations by
electron paramagnetic resonance
Detection of NO production was performed using Fe2+
diethyldithiocarbamate (DETC; Sigma–Aldrich) as spin
trap [22]. Briefly, arteries were treated with 250 μL of
colloid Fe (DETC)2 and incubated for 45 min at 37°C.
Arteries were then frozen in plastic tubes. NO detection
was measured in situ by electron paramagnetic reson-
ance (EPR). Values are expressed as amplitude of signal
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per weight. For O2
•– quantification, arteries were allowed
to equilibrate in deferoxamine-chelated Krebs–acide 4-
(2-hydroxyéthyl)-1-pipérazine ethane sulfonique solution
containing 1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetra-
methylpyrrolidin (Noxygen, Mainz, Germany) (500 μmol/l),
deferoxamine (25 μmol/l) and DETC (5 μmol/l) under con-
stant temperature (37°C) for 20 min. Arteries were then
frozen in plastic tubes and analyzed by EPR spectroscopy.
Values are expressed as units per mg of artery. Sections of
thoracic aorta and mesenteric artery were subjected to
electron spin resonance (ESRR) spectroscopy (Magnet-
tech miniscope MS200, Germany) to quantify O2
•– and
NO production.
Drugs
Phenylephrine, acetylcholine, streptozotocin, sodium ni-
troprusside (SNP), indomethacin, NG-nitro-L-arginine
methyl ester (L-NAME), DETC and deferoxamine were
purchased from Sigma-Aldrich (France). CMH was
purchased from Noxygen (Germany) and PD123319 was
purchased from Tocris Bioscience (United Kingdom).
Divalinal was a kind gift from Dr Jay Wright (Washing-
ton State University, USA). Stock solutions of phenyl-
ephrine, acetylcholine, SNP, and L-NAME were
dissolved in distilled water, streptozotocin was dissolved
in citrate buffer and PD123319 and Divalinal were dis-
solved in water for injection. CMH, DETC and defe-
roxamine were dissolved in Krebs-buffer deoxygenated
by nitrogen flow.
Data analysis
Results were expressed as mean ± SEM. Relaxation of
arteries was expressed as percentage of maximal re-
laxation induced by sodium nitroprusside (10-5 M).
For O2
•– and NO detections, results were expressed
in mean of the ratio in absorbance over the dry
weight in mg (A/mg dry weight). The concentration-
response curves were assessed by analysis of variance
(ANOVA) with repeated measures, followed by Bonferroni
post-hoc tests. Other data were analyzed by analysis
of variance (ANOVA). P < 0.05 indicates significant
difference.
Results
Metabolic and vascular alterations induced by
streptozotocin-induced diabetes
Injection of streptozotocin caused a threefold elevation
of blood glucose by comparison with the control mice
at four, six and eight weeks of diabetes. Furthermore,
streptozotocin-induced diabetes caused a progressive
loss of weight from 4 to 8 weeks and a significant
decrease of systolic blood pressure (Table 1). After
4 weeks of diabetes, aortic rings of the diabetic mice
showed a significant blunting of Acetylcholine-mediated
endothelium-dependent relaxation (EDR). EDR further
impaired progressively with diabetes duration, peaking
at 6 weeks (Figure 1A). In contrast, the SNP-induced
endothelium-independent relaxations were not different
between control and diabetic aortas, even after 8 weeks
of diabetes (data not shown). Morphologic alterations
paralleled the endothelial dysfunction, with a progressive
significant increase of thoracic aorta and mesenteric
artery media thickness, in comparison with control
vessels (Figure 1B).
Angiotensin IV prevents diabetes-induced endothelial
dysfunction
Mice were treated with subcutaneous administration of
AngIV (1.4 mg/kg/d) via an osmotic pump implanted in
the back of the neck immediately prior to induction of
diabetes for 4 weeks. AngIV had no effect on blood
glucose levels, weight loss and blood pressure (Table 1).
However, at week 4, the decrease of endothelium
dependent relaxation induced by diabetes was com-
pletely prevented by AngIV (Figure 2).
Angiotensin IV reverses diabetes-induced endothelial
dysfunction
To determine if AngIV, beyond its preventive effect,
could reverse the vascular alterations induced by dia-
betes, the effect of a rescue treatment implemented after
4 weeks of diabetes has been examined. AngIV was
administrated by a single daily subcutaneous injection
of AngIV (1.4 mg/kg/d in saline) for 15 days, whereas
control mice were treated with the vehicle. Since
the treatment was effective and fully restored aortic
Table 1 Body weight, blood glucose and systolic blood
pressure
Groups Body weight Blood glucose SBP
1st study
Control 38 ± 1* 8.8 ± 0.3* 85 ± 3*
4 w diabetes 28 ± 1 30.9 ± 0.7 68 ± 5
4 w diabetes - angIV 29 ± 1 30.6 ± 0.4 66 ± 3
6 w diabetes 29 ± 1 29.7 ± 0.8 67 ± 3
6 w diabetes - angIV 26 ± 1 30.4 ± 1.1 69 ± 6
8 w diabetes 25 ± 1 33.4 ± 0.8 69 ± 4
2nd study
Agtr2+/+ 32 ± 1 # 9.8 ± 0.8 # 87 ± 3 #
Agtr2+/+ diabetes 25 ± 1 29.3 ± 1.2 67 ± 5
Agtr2-/- 31 ± 1.4 # 9.7 ± 0.6 # 88 ± 3 #
Agtr2-/- diabetes 25 ± 1.4 29.6 ±1.3 66 ± 5
Body weight (g), blood glucose (mmol/l) and systolic blood pressure (mmHg)
are expressed as the mean ± S.E.M, (n = 8-10 per group). Statistical significance
indicated by *p < 0.05 vs. control; # p < 0.05 vs diabetes.
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endothelium-dependent relaxation at the level of the
non-diabetic controls, additional groups of mice were
treated with decreasing doses of AngIV to establish the
dose-response curve. As shown in Figure 3, a significant
shift to the left of the Ach-induced relaxation was
already observed at the dose of 0.03 mg/kg, whereas
0.7 mg/kg was sufficient to fully restore EDR at the level
of non-diabetic controls.
Role of AT2 and AT4 receptors
To determine the respective role of AT2 and AT4 re-
ceptors, two groups of 4 weeks diabetes mice were co-
treated with AngIV (1.4 mg/kg/d) and respectively the
AT4 receptor antagonist Divalinal (2 mg/kg/d) or the
specific AT2 receptor antagonist PD123319 (20 mg/kg/d)
for 15 days. Divalinal completely blunted the protective
effect of AngIV on aortic endothelium-dependent relax-
ation (Figure 4A). In contrast, treatment with PD123319
did not abrogate the protective effect of (Figure 4B).
Since these results were unexpected, we examined the
effect of PD123319 on EDR in diabetic and control
mice in the absence of AngIV. PD123319 had no effect
on EDR in control mice (not shown), but completely
reversed the decrease in EDR induced by diabetes
(Figure 4B).
Effect of AngIV and AT2 receptor blockade on
diabetes-induced vascular remodeling
Analysis of the sections of thoracic aorta (Figure 5A)
and mesenteric arteries (Figure 5B) showed that in
6 weeks diabetes mice, treatment with AngIV prevented
the increase of the media thickness. Also, blockade of
the AT2 receptor with PD123319 from weeks 4 to 6
was equally effective as AngIV to prevent the increase
of aortic and mesenteric media thickness induced by
diabetes. The protective effect of AngIV on media
thickening was abolished in mesenteric arteries, and
was non-significantly attenuated in the aorta sections.
In contrast, in both vascular beds, the protective ac-
tion of AngIV was unaffected by cotreatment with
PD123319.
Production of nitric oxide and superoxide anion
After 6 weeks streptozotocin-induced diabetes signifi-
cantly decreased NO production both in the aortic
(Figure 6A) and mesenteric (Figure 6B) vessels. In
both vascular beds, treatment with AngIV or
PD123319 prevented the decrease of NO induced by
diabetes (Figure 6A and B).
The analysis of the production of superoxide anion
showed that streptozotocin-induced diabetes significantly
Figure 1 Vascular alterations induced by diabetes. Time course of the reduction of endothelium-dependent relaxations in the aorta after
4, 6 and 8 weeks of diabetes (A). Time course of the increase of aortic and mesenteric media thickness (B). *p < 0.05; **p < 0.01; ***p < 0.001
versus control.
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enhanced O2
•- production both in thoracic aorta (Fig-
ure 6C) and mesenteric arteries (Figure 6D), whereas
AngIV or PD123319 prevented, respectively, the en-
hancement induced by diabetes in both vascular beds
(Figure 6C and D).
Effect of diabetes on EDR and media thickness in mice
lacking the AT2 receptor
Treatment with streptozotocin induced a three-fold in-
crease in glucose blood levels, associated with a signifi-
cant decrease of body weight and systolic blood pressure
of comparable amplitude in control wild type (Agtr2+/+)
and AT2 receptor deleted (Agtr2-/-) mice (Table 1).
Figure 2 Chronic AngIV treatment prevents endothelial
dysfunction. Concentration-response curves for ACh in aorta for
control, 4 weeks diabetes, and 4 weeks diabetes treated with AngIV
(1.4 mg/kg/d). Mice were treated at the beginning of diabetes for a
period of 4 weeks. Statistical significance between 4 weeks diab and
4 weeks diab + AngIV indicated by # p < 0.05.
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Figure 3 Dose dependent effect of chronic treatment with
AngIV in 6 weeks diabetic mice on endothelial function.
Concentration-response curves for ACh in thoracic aorta for control,
6 weeks diabetic mice, and 6 weeks diabetic mice treated during the
last two weeks with AngIV (0.01 or 0.03 or 0.1 or 0.7 or 1.4 mg/kg/d).
Statistical significance between 6 weeks diab and 6 weeks treated
groups indicated by # # # p < 0.001.
Figure 4 Effect of chronic cotreatment with AngIV or PD123319
in 6 weeks diabetic mice on endothelial function. (A) Mice were
treated for two weeks after 4 weeks of diabetes initiation with
vehicle (6 w diab), AngIV 1.4 mg/kg/day alone (6 w diab + AngIV),
or combined with the specific AT4 antagonist Divalinal 2 mg/kg/d
(6 w diab + AngIV + Div). # # # p < 0.001 for AngIV + Divalinal versus
AngIV alone. (B) Mice were treated for two weeks after 4 weeks
of diabetes initiation with the specific AT2 antagonist PD123319
20 mg/kg/d (6 w diab + PD) alone or in combination with AngIV
(6 w diab + AngIV + PD). #versus (diab).
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Acetylcholine cumulative concentration–response
curves were obtained after phenylephrine-induced pre-
constriction of mesenteric arteries of control wild type
(Agtr2+/+) and AT2 receptor deleted (Agtr2-/-). While
endothelium-dependent relaxation was markedly re-
duced by diabetes in Agtr2+/+ mice, no difference be-
tween control and diabetic group has been shown in
Agtr2-/- mice. In Agtr2+/+ mice, diabetes induced a sig-
nificant increase of the mesenteric artery media thick-
ness whereas no change has been shown in Agtr2-/-
mice between control and diabetic groups (Figure 7B).
Discussion
The present study provides evidence that AT2 and AT4
receptors have opposite effects on vascular alteration
caused by streptozotocin-induced diabetes in mice, a find-
ing that provides new light on the complex role of the
renin-angiotensin- system on the diabetes-induced vascu-
lar alteration, and may provide new therapeutic tracks for
optimizing vascular prevention in diabetes patients.
Diabetes is associated with both microvascular and macro-
vascular diseases, manifested as altered vascular morphology
and function. Thus, vascular smooth muscle cells (VSMCs)
Figure 5 Tunica media thickness. Sections for thoracic aorta (A) and mesenteric artery (B) for control group (control) and 6 weeks diabetes
groups treated for the last two weeks with vehicle (6 w diab), AngIV (6 w diab + AIV), AngIV and Divalinal (6 w diab + AIV + Div), AngIV and
PD123319 (6 w diab + AIV + PD), or PD123319 alone (6 W diab + PD). *p <0.05 and **p < 0.01 versus control; # p < 0.05 and # # p < 0.01 versus
6w diab, § p < 0.05 versus 6w diab + AIV.
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exposed to elevated glucose [23] and aortic smooth muscle
cells from diabetic rabbits or rats exhibit increased in vitro
growth rates [24]. Endothelial dysfunction is an early feature
of diabetic vascular disease, characterized by a decrease in
NO bioavailability and a concomitant increase in vascular
O2
•- formation [25]. Loss of NO bioavailability precedes the
development of overt atherosclerosis and is an independent
predictor of adverse cardiovascular events [26,27].
In our study, induction of diabetes with streptozotocin
in young mice induced the well-recognized vascular
alterations, with a progressive dysfunction of endothe-
lium-dependent relaxation and hypertrophy of the media
in both aortic and mesenteric vascular beds, peaking
after 6 weeks of diabetes duration. In this classical ex-
perimental model, we demonstrate that treatment with
AngIV prevented the functional endothelial alteration
and the vascular hypertrophy induced by diabetes.
Moreover, when implemented in mice with already
established vascular alteration, treatment with AngIV
dose-dependently restored functional and morphologic
vascular integrity. AngIV did not mediate its favorable
actions via effects on metabolic or hemodynamic path-
ways such as glucose or blood pressure, respectively, two
major pathways in the pathogenesis of diabetic vascular
disease [28,29]. Consistent with the observed antitrophic
effect, direct measurement by electron paramagnetic res-
onance showed that AngIV restored a normal balance
between the content of NO and superoxide anion in the
aortic and mesenteric walls. Taken together, our results
fully confirm, and extend to the model of experimental
type 1 diabetes the beneficial effect of chronic AngIV treat-
ment first reported by Vinh et al. in Apo-E deficient mice
[19], and further establish that AngIV acts by increasing
NO bioavailability and decreasing oxidative stress.
However, our findings yield opposite conclusions as
regards the respective contribution of AT2 and AT4
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Figure 6 Nitric oxide and anion superoxide production. (A, B) Nitric oxide and (C, D) O2
- production in thoracic aorta sections (A, C) and
mesenteric artery (B, D) of control mice, 6 weeks diabetic mice (6 w diab), and 6 weeks diabetic mice treated during the last two weeks with
AngIV (6 w diab + AIV)) or PD 123319 (6 w diab + PD)). *p <0.05 and ***p < 0.001 versus control; # p < 0.05 and # # p < 0.01 versus 6w diab.
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receptors in mediating the actions of AngIV. In the
Apo-E deficient mice model, the protective effect of
AngIV on endothelial dysfunction was attenuated by
both the specific AT4 antagonist Divalinal and the AT2
antagonist PD123319, suggesting involvement of both
receptors [18]. In a previous work, our group has re-
ported that AngIV was protective in a model of acute
ischemic stroke, and that both AT2 and AT4 antagonists
likewise inhibited this protective effect [30]. In contrast
in our diabetic mice, Divalinal completely blunted the
protective effect of AngIV on EDR, whereas PD123319
had no effect. To further examine the role of the
AT2 receptor, we thus studied the effect of AT2
pharmacological blockade in the absence of AngIV, and
found that PD123319 had no effect on EDR in control
mice, but completely blunted the diabetes-induced
alteration of EDR. In the ApoE-deficient mice, AngIV
blunted the increase of dihydroethidium staining for
superoxide and PD123319 significantly inhibited this
effect of AngIV. In sharp contrast we found that both
AngIV and PD123319 equally inhibited diabetes-induced
increase of superoxide production. Thus, the protective
effect of AngIV in the atherogenic model of ApoE-
deficient mice appears to be mediated by both AT2 and
AT4 receptors, whereas in streptozotocin-induced dia-
betes mice, the protective effect of AngIV was solely me-
diated by AT4, while AT2 receptor stimulation seemed
to play a detrimental role. This puzzling observation led
us to extend our study and to further examine the role
of AT2 by studying the effect of diabetes on vascular al-
terations in genetically modified mice lacking the AT2
receptor. In full consistence with the results gained with
the pharmacological blockade of the AT2 receptor, we
found that AT2 null mice were fully protected against
the endothelial dysfunction and the vascular hypertrophy
of the mesenteric arteries induced by six weeks of
diabetes. In a study performed in ApoE/ AT1A receptor
double knockout mice [31], chronic AT2 receptor inhib-
ition with PD123319 increased plaque development,
whereas direct AT2 receptor stimulation reduced ather-
ogenesis, demonstrating, in accordance with Vinh et al.,
an antiatherosclerotic role of the AT2 receptor. However,
Koitka et al. [32] reported that in ApoE-deficient mice, in-
duction of diabetes with streptozotocin increased the aor-
tic expression of the gene Agt2r, and was associated with a
six-fold increase in plaque area that was significantly at-
tenuated by both AT2R pharmacological blockade and
AT2R deletion.
These patent discrepancies regarding the role of the AT2
receptor, that appears to be protective in the ApoE-
deficient model of accelerated atherosclerosis, but detri-
mental in the setting of diabetes in fact no really surprising,
and adds to a long list of controversial data. Left ventricular
hypertrophy (LVH) is a major predictor of cardiovascular
morbidity and mortality, and it is unanimously accepted
that the angiotensin AT1 receptor is involved in the patho-
genesis of hypertension and LVH, but the role of the AT2
receptor in LVH is still controversial. Studies addressing
the involvement of the AT2 receptor in LVH performed in
genetically altered, either AT2 receptor-deficient or AT2
receptor-overexpressing yielded highly controversial results
with an equal number of studies supporting prohyper-
trophic, antihypertrophic, or neutral effects of the AT2
receptor in LVH [33].
These discrepancies have been discussed in deep else-
where [34], and support the view that the mysterious
versatility of the AT2 receptor phenotype appears to be
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Figure 7 Effect of diabetes in AT2R deficient mice. Effect of
6 weeks diabetes on mesenteric arteries endothelial dependent
relaxation (A) and media thickness (B) in wild-type (Agtr2+/+) and
AT2R deficient mice (Agtr2-/-), treated (Diab) or not with STZ, n = 5
in each group; *p <0.05 and **p < 0.01 versus control.
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highly cell-type and tissue specific, but also to depend
on the autocrine/paracrine regulation of the cellular mi-
lieu of the target organs, and the specific experimental
or pathophysiological conditions that determine the
complex cross-talk between AT1 and AT2 receptors. For
instance, You et al. [35] have shown that high blood
pressure reversed the classical AT2 receptor-mediated
vasodilation into vasoconstriction in spontaneously
hypertensive rats, in agreement with a previous study
showing that in young hypertensive rats AngII-induced
contraction was decreased by AT2R blockade [36]. The
mechanism of this reversal remains to be discovered, but
may involve a switch in signaling from constrictor to
dilator mechanisms due to increased endothelial AT2R
expression. AT2R-dependent contraction in SHR is
not affected by endothelium removal whereas AT2R-
dependent dilation is abolished in the absence of endo-
thelium. Thus the difference in the type of response
might reflect a change in AT2R expression between the
endothelium and the smooth muscle.
A recent study tested the effects of a 2 weeks treat-
ment with the AT2 receptor agonist CGP-42112A on in-
flammation and oxidative stress in obese Zucker rats
and compared them to their lean counterparts: the re-
sults suggested anti-inflammatory and antioxidative
functions of AT2 receptor in obese Zucker rats, but pro-
inflammatory and prooxidative functions in lean Zucker
rats [37] further suggesting that AT2R function depends
on the pathophysiological context.
In our study, diabetes was induced by streptozotocin, a
convenient and widely used experimental model that is
not devoid of criticisms and limitations. Noticeably,
streptozotocin induces diabetes, but also elicits a strong
and sustained inflammatory state. It is thus clearly pos-
sible that the deleterious effect of AT2R herein reported
is the consequence of streptozotocin-induced side effects
rather than that of diabetes per se, and the potential role
of AT2R needs to be further studied in other experimen-
tal models of diabetes. Nonetheless, the observation that,
in given experimental conditions, the AT2 receptor
stimulation has a deleterious effect on vascular func-
tional and morphological integrity challenge the concept
that AT2 receptor stimulation represents the counter-
regulatory arm of the RAS that unequivocally balances
and opposes the effects of AT1 stimulation. Indeed, in
spite of the uncertainties and discrepancies regarding
AT2 functions, the view has emerged that the physio-
logical functions of AT2 receptor is to antagonize the ef-
fects of the AT1 receptor [38], and that novel strategies
to improve cardiovascular diseases may rely on drugs
activating the tissue-protective arms of RAAS [39,40]
The discovery of a first non-peptide, orally active AT2-
receptor agonist compound 21 (C21), that should enter
soon the first steps of clinical studies will help to clarify
the therapeutic potential of AT2 stimulation [41], but
our findings stress the need to cautiously delineate the
specific pathological conditions in which it may prove
beneficial, or in contrary may reveal potentially harmful.
During the last decade, AT4 has been identified
as insulin-regulated aminopeptidase (IRAP) [42]. The
nature of the molecular mechanism by which this
membrane-bound enzyme mediates the variety of intra-
cellular signaling and the biological effects triggered by
AngIV remains so far obscure, and several hypotheses
are still debated (see [43] for review). Interest on AngIV/
AT4 (IRAP) pathway has nonetheless been boosted by
its potential ability to enhance cognitive function and
memory [44]. This potential interest as prompted active
ongoing research to identify small biologically active
non-peptides molecules that, like AngIV, inhibit the
catalytic domain of IRAP [45]. Such new AT4 agonists
will pave the way for innovative research for the preven-
tion of cognitive decline, but also for stroke therapy
[30,46,47]. Clearly our present findings, confirming the
vascular protective effect of AngIV in type 1 diabetes
mice also invite to consider AT4/IRAP as another poten-
tial target for revisited therapeutic strategies of RAAS
modulation for cardiovascular disease prevention.
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